Skip to main content
Erschienen in: Tumor Biology 6/2010

01.12.2010 | Research Article

CDC25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma

verfasst von: Isik Didem Karagoz, Mehmet Ozaslan, Beyhan Cengiz, Mehmet Emin Kalender, Ibrahim Halil Kilic, Serdar Oztuzcu, Bulent Gogebakan, Abdullah Tuncay Demiryurek

Erschienen in: Tumor Biology | Ausgabe 6/2010

Einloggen, um Zugang zu erhalten

Abstract

The family of cell division cycle 25 (CDC25) phosphatase is one of the important regulators of the cell cycle progression. In mammalian cells, three isoforms have been identified: CDC25A, CDC25B, and CDC25C. CDC25A is required to enter S time, and the overexpression of this phosphatase accelerates the entrance to S time. CDC25A overexpression could render tumor cells less sensitive to DNA replication checkpoints, thereby contributing to their genomic instability. We aimed to investigate, for the first time, the frequency of human CDC25A gene SNPs in metastatic and non-metastatic breast cancer. Total number of 281 eligible patients with histologically confirmed incident of breast cancer and 137 cancer-free controls were included. The detection of CDC25A gene polymorphisms was achieved with real-time polymerase chain reaction and restriction fragment length polymorphism techniques. We found that the 263C/T polymorphism was significantly associated with breast cancer and risk of metastasis. The -350C/T polymorphism in the promoter region of CDC25A gene was found to associate with neither breast cancer nor metastasis. The other promoter polymorphism -51C/G in the CDC25A gene associated with breast cancer but not associated with metastasis. These data suggest that 263C/T and -51C/G polymorphisms of CDC25A gene could be candidate markers for earlier diagnosis and targets for breast cancer therapy.
Literatur
1.
Zurück zum Zitat Gürtunç E: Meme Kanserli Hastalarda CYP19 Geni Kodon 39 Trp/Arg Polimorfizminin ve Genotip Dağılımının Araştırılması. Yüksek Lisans Tezi. Çukurova Üniv Sağlık Bilimleri Ens Tıbbi Biyoloji ABD 2007. Gürtunç E: Meme Kanserli Hastalarda CYP19 Geni Kodon 39 Trp/Arg Polimorfizminin ve Genotip Dağılımının Araştırılması. Yüksek Lisans Tezi. Çukurova Üniv Sağlık Bilimleri Ens Tıbbi Biyoloji ABD 2007.
2.
Zurück zum Zitat Yıldız Y: Meme Kanserli Hastalarda TNF ile İlişkili Apoptoz Uyarıcı Ligand ve Bcl-2 ile İlişkili X-Protein Gen Polimorfizmlerinin Araştırılması. Yüksek Lisans Tezi. İstanbul Üniv Sağlık Bilimleri Ens Moleküler Tıp ABD 2008. Yıldız Y: Meme Kanserli Hastalarda TNF ile İlişkili Apoptoz Uyarıcı Ligand ve Bcl-2 ile İlişkili X-Protein Gen Polimorfizmlerinin Araştırılması. Yüksek Lisans Tezi. İstanbul Üniv Sağlık Bilimleri Ens Moleküler Tıp ABD 2008.
3.
Zurück zum Zitat Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 2006;240:261–7.CrossRefPubMed Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J, et al. Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett. 2006;240:261–7.CrossRefPubMed
4.
Zurück zum Zitat Hossfeld DK, Sherman CD, Love RR, Bosch FX: Klinik Onkoloji. Uluslararası Kanserle Savaş Birliği 1992; 5th edition, p 25. Hossfeld DK, Sherman CD, Love RR, Bosch FX: Klinik Onkoloji. Uluslararası Kanserle Savaş Birliği 1992; 5th edition, p 25.
5.
Zurück zum Zitat Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? good targets? Nat Rev Cancer. 2007;7:495–507.CrossRefPubMed Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? good targets? Nat Rev Cancer. 2007;7:495–507.CrossRefPubMed
6.
Zurück zum Zitat Cangi MG, Cukor B, Soung P, Signoretti S, Moreira Jr G, Ranashinge M, et al. Role of the CDC25A phosphatase in human breast cancer. J Clin Invest. 2000;106:753–61.CrossRefPubMed Cangi MG, Cukor B, Soung P, Signoretti S, Moreira Jr G, Ranashinge M, et al. Role of the CDC25A phosphatase in human breast cancer. J Clin Invest. 2000;106:753–61.CrossRefPubMed
7.
Zurück zum Zitat Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, et al. CDC25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 1994;13:1549–56.PubMed Jinno S, Suto K, Nagata A, Igarashi M, Kanaoka Y, Nojima H, et al. CDC25A is a novel phosphatase functioning early in the cell cycle. EMBO J. 1994;13:1549–56.PubMed
8.
Zurück zum Zitat Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human CDC25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 1994;13:4302–10.PubMed Hoffmann I, Draetta G, Karsenti E. Activation of the phosphatase activity of human CDC25A by a cdk2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 1994;13:4302–10.PubMed
9.
Zurück zum Zitat Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.CrossRefPubMed Boutros R, Dozier C, Ducommun B. The when and wheres of CDC25 phosphatases. Curr Opin Cell Biol. 2006;18:185–91.CrossRefPubMed
10.
Zurück zum Zitat Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human CDC25A inactivation in response to S time inhibition and its role in preventing premature mitosis. EMBO Rep. 2000;1:71–9.CrossRefPubMed Molinari M, Mercurio C, Dominguez J, Goubin F, Draetta GF. Human CDC25A inactivation in response to S time inhibition and its role in preventing premature mitosis. EMBO Rep. 2000;1:71–9.CrossRefPubMed
11.
Zurück zum Zitat Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S, et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 1997;57:2366–8.PubMed Gasparotto D, Maestro R, Piccinin S, Vukosavljevic T, Barzan L, Sulfaro S, et al. Overexpression of CDC25A and CDC25B in head and neck cancers. Cancer Res. 1997;57:2366–8.PubMed
12.
Zurück zum Zitat Hernandez S, Hernandez L, Bea S, Cazorla M, Fernandez PL, Nadal A, et al. CDC25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin’s lymphomas. Cancer Res. 1998;58:1762–7.PubMed Hernandez S, Hernandez L, Bea S, Cazorla M, Fernandez PL, Nadal A, et al. CDC25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin’s lymphomas. Cancer Res. 1998;58:1762–7.PubMed
13.
Zurück zum Zitat Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, et al. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res. 1997;88:947–52.PubMed Kudo Y, Yasui W, Ue T, Yamamoto S, Yokozaki H, Nikai H, et al. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res. 1997;88:947–52.PubMed
14.
Zurück zum Zitat Wu W, Fan Y, Kemp B, Walsh G, Mao L. Overexpression of CDC25A and CDC25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998;58:4082–5.PubMed Wu W, Fan Y, Kemp B, Walsh G, Mao L. Overexpression of CDC25A and CDC25B is frequent in primary non-small cell lung cancer but is not associated with overexpression of c-myc. Cancer Res. 1998;58:4082–5.PubMed
15.
Zurück zum Zitat Moreira Jr G, Colleoni GWB, Cangi MG, Murphy M, Sherburne B, et al. Reciprocal CDC25A and p27 expression in B-cell non-Hodgkin lymphomas. Diagn Mol Pathol. 2003;12(3):128–32. Moreira Jr G, Colleoni GWB, Cangi MG, Murphy M, Sherburne B, et al. Reciprocal CDC25A and p27 expression in B-cell non-Hodgkin lymphomas. Diagn Mol Pathol. 2003;12(3):128–32.
16.
Zurück zum Zitat Hernandez S, Bessa X, Bea S, Hernandez L, Nadal A, Mallofre C, et al. Differential expression of CDC25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest. 2001;81:465–73.PubMed Hernandez S, Bessa X, Bea S, Hernandez L, Nadal A, Mallofre C, et al. Differential expression of CDC25 cell-cycle-activating phosphatases in human colorectal carcinoma. Lab Invest. 2001;81:465–73.PubMed
17.
Zurück zum Zitat Ray D, Kiyokama H. CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res. 2008;68(5):1251–3.CrossRefPubMed Ray D, Kiyokama H. CDC25A phosphatase: a rate-limiting oncogene that determines genomic stability. Cancer Res. 2008;68(5):1251–3.CrossRefPubMed
18.
Zurück zum Zitat Cangi MG, Piccinin S, Pecciarini L, Talarico A, Cin ED, Grassi S, et al. Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites. Int J Cancer. 2008;123:1466–71.CrossRefPubMed Cangi MG, Piccinin S, Pecciarini L, Talarico A, Cin ED, Grassi S, et al. Constitutive overexpression of CDC25A in primary human mammary epithelial cells results in both defective DNA damage response and chromosomal breaks at fragile sites. Int J Cancer. 2008;123:1466–71.CrossRefPubMed
20.
Zurück zum Zitat Cozma D, Lukes L, Rouse J, Qiu TH, Liu ET, Hunter KW. A bioinformatics-based strategy identifies c-Myc and CDC25A as candidates for the Apmt mammary tumour latency modifiers. Genome Res. 2002;12:969–75.CrossRefPubMed Cozma D, Lukes L, Rouse J, Qiu TH, Liu ET, Hunter KW. A bioinformatics-based strategy identifies c-Myc and CDC25A as candidates for the Apmt mammary tumour latency modifiers. Genome Res. 2002;12:969–75.CrossRefPubMed
21.
Zurück zum Zitat Ito Y, Yoshida H, Uruno T, Takamura Y, Miya A, Kuma K, et al. Expression of CDC25A and CDC25B phosphatase in breast carcinoma. Breast Cancer. 2004;11:295–300.CrossRefPubMed Ito Y, Yoshida H, Uruno T, Takamura Y, Miya A, Kuma K, et al. Expression of CDC25A and CDC25B phosphatase in breast carcinoma. Breast Cancer. 2004;11:295–300.CrossRefPubMed
Metadaten
Titel
CDC25A gene 263C/T, -350C/T, and -51C/G polymorphisms in breast carcinoma
verfasst von
Isik Didem Karagoz
Mehmet Ozaslan
Beyhan Cengiz
Mehmet Emin Kalender
Ibrahim Halil Kilic
Serdar Oztuzcu
Bulent Gogebakan
Abdullah Tuncay Demiryurek
Publikationsdatum
01.12.2010
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 6/2010
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0075-z

Weitere Artikel der Ausgabe 6/2010

Tumor Biology 6/2010 Zur Ausgabe

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

CUP-Syndrom: Künstliche Intelligenz kann Primärtumor finden

30.04.2024 Künstliche Intelligenz Nachrichten

Krebserkrankungen unbekannten Ursprungs (CUP) sind eine diagnostische Herausforderung. KI-Systeme können Pathologen dabei unterstützen, zytologische Bilder zu interpretieren, um den Primärtumor zu lokalisieren.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.